An adverse outcome pathway on the disruption of retinoic acid metabolism leading to developmental craniofacial defects. (30th June 2021)
- Record Type:
- Journal Article
- Title:
- An adverse outcome pathway on the disruption of retinoic acid metabolism leading to developmental craniofacial defects. (30th June 2021)
- Main Title:
- An adverse outcome pathway on the disruption of retinoic acid metabolism leading to developmental craniofacial defects
- Authors:
- Menegola, Elena
Veltman, Christina H.J.
Battistoni, Maria
Di Renzo, Francesca
Moretto, Angelo
Metruccio, Francesca
Beronius, Anna
Zilliacus, Johanna
Kyriakopoulou, Katerina
Spyropoulou, Anastasia
Machera, Kyriaki
van der Ven, Leo T.M.
Luijten, Mirjam - Abstract:
- Abstract: Adverse outcome pathway (AOP) is a conceptual framework that links a molecular initiating event (MIE) via intermediate key events (KEs) with adverse effects (adverse outcomes, AO) relevant for risk assessment, through defined KE relationships (KERs). The aim of the present work is to describe a linear AOP, supported by experimental data, for skeletal craniofacial defects as the AO. This AO was selected in view of its relative high incidence in humans and the suspected relation to chemical exposure. We focused on inhibition of CYP26, a retinoic acid (RA) metabolizing enzyme, as MIE, based on robust previously published data. Conazoles were selected as representative stressors. Intermediate KEs are RA disbalance, aberrant HOX gene expression, disrupted specification, migration, and differentiation of neural crest cells, and branchial arch dysmorphology. We described the biological basis of the postulated events and conducted weight of evidence (WoE) assessments. The biological plausibility and the overall empirical evidence were assessed as high and moderate, respectively, the latter taking into consideration the moderate evidence for concordance of dose-response and temporal relationships. Finally, the essentiality assessment of the KEs, considered as high, supported the robustness of the presented AOP. This AOP, which appears of relevance to humans, thus contributes to mechanistic underpinning of selected test methods, thereby supporting their application inAbstract: Adverse outcome pathway (AOP) is a conceptual framework that links a molecular initiating event (MIE) via intermediate key events (KEs) with adverse effects (adverse outcomes, AO) relevant for risk assessment, through defined KE relationships (KERs). The aim of the present work is to describe a linear AOP, supported by experimental data, for skeletal craniofacial defects as the AO. This AO was selected in view of its relative high incidence in humans and the suspected relation to chemical exposure. We focused on inhibition of CYP26, a retinoic acid (RA) metabolizing enzyme, as MIE, based on robust previously published data. Conazoles were selected as representative stressors. Intermediate KEs are RA disbalance, aberrant HOX gene expression, disrupted specification, migration, and differentiation of neural crest cells, and branchial arch dysmorphology. We described the biological basis of the postulated events and conducted weight of evidence (WoE) assessments. The biological plausibility and the overall empirical evidence were assessed as high and moderate, respectively, the latter taking into consideration the moderate evidence for concordance of dose-response and temporal relationships. Finally, the essentiality assessment of the KEs, considered as high, supported the robustness of the presented AOP. This AOP, which appears of relevance to humans, thus contributes to mechanistic underpinning of selected test methods, thereby supporting their application in integrated new approach test methodologies and strategies and application in a regulatory context. … (more)
- Is Part Of:
- Toxicology. Volume 458(2021)
- Journal:
- Toxicology
- Issue:
- Volume 458(2021)
- Issue Display:
- Volume 458, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 458
- Issue:
- 2021
- Issue Sort Value:
- 2021-0458-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-06-30
- Subjects:
- AOP -- Craniofacial defects -- Cyp 26 inhibition -- Conazoles -- Retinoic acid
Toxicology -- Periodicals
Chemicals -- Physiological effect -- Periodicals
615.9005 - Journal URLs:
- http://www.sciencedirect.com/science/journal/0300483X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.tox.2021.152843 ↗
- Languages:
- English
- ISSNs:
- 0300-483X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8873.035000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18299.xml